Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.

Maziarz, Richard T; Schuster, Stephen J; Romanov, Vadim V; Rusch, Elisha S; Li, Junlong; Signorovitch, James E; Maloney, David G; Locke, Frederick L

Maziarz, Richard T; Schuster, Stephen J; Romanov, Vadim V; Rusch, Elisha S; Li, Junlong; Signorovitch, James E; Maloney, David G; Locke, Frederick L.

Afiliação

Maziarz RT; Center for Hematologic Malignancies, Oregon Health & Science Knight Cancer Institute, Portland, OR.
Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Romanov VV; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
Rusch ES; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
Li J; Health Economics and Outcomes Research, Analysis Group, Inc., Boston, MA.
Signorovitch JE; Health Economics and Outcomes Research, Analysis Group, Inc., Boston, MA.
Maloney DG; Fred Hutchinson Cancer Research Center, Seattle, WA; and.
Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL.

Blood Adv ; 4(7): 1440-1447, 2020 04 14.

Article em En | MEDLINE | ID: mdl-32271898

Assuntos

Antígenos CD19; Receptores de Antígenos de Linfócitos T; Adulto; Humanos; Imunoterapia Adotiva; Receptores de Antígenos de Linfócitos T/genética; Estudos Retrospectivos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Antígenos CD19 Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Blood Adv Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google